A bipartisan legislative proposal aims to allow board-certified physicians to prescribe methadone for opioid use disorder directly via pharmacy pickup, potentially bypassing current federal restrictions that limit methadone dispensing to specialized clinics.
A randomized clinical trial indicates that using personalized brain imaging to guide transcranial magnetic stimulation (TMS) improves outcomes for patients with treatment-resistant depression.
Personalized fMRI-guided targeting of accelerated TMS improves depression response rates to 80% compared to 60% with standard scalp targeting.
A randomized controlled trial demonstrates that smokers with a 'sign-tracker' neuroaffective profile achieve significantly higher abstinence rates with varenicline compared to nicotine replacement therapy, supporting biomarker-guided prescribing for smoking cessation.
A double-blind RCT demonstrates that neurobiomarker-guided repetitive transcranial magnetic stimulation (rTMS) yields greater depressive symptom improvement than sham in youth with major depressive episodes, supporting precision neuromodulation strategies.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 30 – Jun 25)
- Consider prescribing centanafadine as a first-in-class NDSRI option for adult ADHD patients who have comorbid anxiety, given its positive phase 3b trial results.
- Utilize ketamine infusions for the rapid reduction of acute major depressive symptoms when immediate relief is clinically necessary.
- Incorporate ketamine-assisted psychotherapy to create psychological space that may facilitate engagement in treatment for patients with methamphetamine use disorder.
- Assess for a 'sign-tracker' neuroaffective profile in smokers, as these patients achieve significantly higher abstinence rates with varenicline compared to nicotine replacement therapy.
- Monitor stroke risk carefully when prescribing SSRIs versus non-SSRI antidepressants, using recent meta-analysis data to inform cardiovascular safety decisions.
- Implement personalized brain imaging guidance for transcranial magnetic stimulation (TMS) in treatment-resistant depression to improve clinical outcomes over standard targeting.
- Apply neurobiomarker-guided repetitive TMS as a precision neuromodulation strategy for youth with major depressive episodes, given evidence of greater symptom improvement than sham.
- Target accelerated TMS using personalized fMRI guidance to potentially increase depression response rates up to 80% compared to standard scalp targeting methods.
Diagnosis & Treatment 2
A meta-analysis published in JAMA Psychiatry confirms that ketamine infusions rapidly reduce symptoms of major depressive episodes during the acute phase.
This meta-analysis compares stroke risk between patients treated with SSRIs versus non-SSRI antidepressants, providing evidence relevant to cardiovascular safety in psychiatric prescribing.
Substance Use 1
Qualitative data from an open-label pilot suggest ketamine-assisted psychotherapy creates 'psychological space' that facilitates engagement in treatment for methamphetamine use disorder, though sustained behavioral change remains variable.
Drug Development 1
Otsuka reports positive phase 3b trial results for centanafadine in adults with ADHD and comorbid anxiety, supporting its pending FDA approval as a first-in-class NDSRI.